Abstract: Disclosures of the present invention describe a method of treatment of cancer cells by using pharmaceutical composition. In the present invention, it particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a pharmaceutical composition for use in causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, related experimental data have proved that, the pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

Abstract: Disclosures of the present invention describe an unsaturated-fatty-acid-containing vegetarian composition, wherein the said composition is composed by at least one vegetable oil and at least one algal oil, and rich in Omega-3, Omega-6 and Omega-9. The present invention particularly design the constituting ratio of Omega-3, Omega-6, and Omega-9 in order to facilitate the content levels of Omega-3 and Omega-6 in the body of a vegetarian administering the vegetarian composition of the present invention reach an ideal balance state. Moreover, it is worth introducing that, this vegetarian composition can be accommodated by a vegetable capsule shell, so as to become a capsule type of dietary supplement. Therefore, it is a great relief for vegetarians to administer the vegetarian composition containing unsaturated fatty acids because the vegetarian composition is made of vegan materials.

Abstract: Disclosures of the present invention describe a method of treatment of cancer cells by using pharmaceutical composition. In the present invention, it particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a pharmaceutical composition for use in causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, related experimental data have proved that, the pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

Abstract: An anti-cancer drug composition includes a Ganoderma extract having a concentration of 1-5 mg/ml and an amphotericin B having a concentration of 3-10 ?M. The Ganoderma extract and the amphotericin B are medicated at different times by pre-treating cancer cells with the Ganoderma extract for a period of time followed by administration of the amphotericin B to enhance an anti-cancer effect of the amphotericin B.

Abstract: The present invention provides a composition for inhibiting renal cancer cell growth and enhancing kidney function. This composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering this composition of 7 mg/day/kg to the patient for 20 days. Moreover, because the cell biological experiments have proved that the of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.

Abstract: The present invention provides a composition for enhancing immunity. Differing from all commercial vitamin healthcare foods would cause some adverse effects due to excessive vitamin intake, the present invention proposes a Solanum nigrum-fermented product to be a novel composition for enhancing immunity. Moreover, animal experimental results have proved that, this novel composition would not cause any adverse effects (such as poor appetite or liver damage) even if an adult excessively administer the novel composition. In addition, comparing with the commercial healthcare foods always being made to tablets, the Solanum nigrum-fermented product (i.e., the novel composition) can be processed to various forms, such as powder, tablet, capsule, and drink.

Abstract: The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient.

Abstract: Differing from commercial dietary supplements of EPA and DHA are made by using abyssal fishes as primary raw materials, the present invention provides an unsaturated-fatty-acid-containing vegetarian composition, wherein the said composition is composed by at least one vegetable oil and at least one algal oil, and rich in Omega-3, Omega-6 and Omega-9. The present invention particularly design the constituting ratio of Omega-3, Omega-6, and Omega-9 in order to facilitate the content levels of Omega-3 and Omega-6 in the body of a vegetarian administering the vegetarian composition of the present invention reach an ideal balance state. Moreover, it is worth introducing that, this vegetarian composition can be accommodated by a vegetable capsule shell, so as to become a capsule type of dietary supplement. Therefore, it is a great relief for vegetarians to administer the vegetarian composition containing unsaturated fatty acids because the vegetarian composition is made of vegan materials.

Abstract: The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient.

Abstract: The present invention provides a composition having functionality to enhance immunity. Differing from all commercial vitamin healthcare foods would cause some adverse effects due to excessive vitamin intake, the present invention proposes a Solanum nigrum-fermented product to be a novel composition having functionality to enhance immunity. Moreover, animal experimental results have proved that, this novel composition would not cause any adverse effects (such as poor appetite or liver damage) even if an adult excessively administer the novel composition. In addition, comparing with the commercial healthcare foods always being made to tablets, the Solanum nigrum-fermented product (i.e., the novel composition) can be processed to various forms, such as powder, tablet, capsule, and drink.

Abstract: The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a novel pharmaceutical composition for causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

Abstract: The present invention provides an Antrodia camphorata and Ganoderma lucidum composition having functionality to inhibit renal cancer cell growth and enhance kidney function. This navel composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering low-dosage Antrodia camphorata and Ganoderma lucidum composition of 7 mg/day/kg to the patient for 20 days.

Abstract: An anti-cancer drug composition includes a Ganoderma extract having a concentration of 1-5 mg/ml and an amphotericin B having a concentration of 3-10 ?M. The Ganoderma extract and the amphotericin B are medicated at different times by pre-treating cancer cells with the Ganoderma extract for a period of time followed by administration of the amphotericin B to enhance an anti-cancer effect of the amphotericin B.